), a global leader in medical devices used in critical care and
surgery, recently closed its earlier announced acquisition of all
the assets of Willemstad, Netherlands based LMA International
N.V. as well as LMA's branded laryngeal mask supraglottic airway
business and other equipments of Intavent Direct Limited.
BARD C R INC (BCR): Free Stock Analysis
CAREFUSION CORP (CFN): Free Stock Analysis
COVIDIEN PLC (COV): Free Stock Analysis
TELEFLEX INC (TFX): Free Stock Analysis
To read this article on Zacks.com click here.
Conjointly, Teleflex expects the acquisitions to be accretive to
the company's adjusted earnings per share in the range of 3 cents
to 4 cents for 2012 and 35 cents to 40 cents for 2013. This
projection excludes non-recurring purchase accounting items and
other costs associated with takeovers and mergers.
The acquisition will enhance Teleflex's anesthesia product line
as LMA is a global provider of medical equipment to anesthetists.
LMA is also considered to be a worldwide leader in laryngeal
masks which will allow Teleflex to gain market leading position
for this offering.
Collectively, these acquisitions will expand Teleflex's
anesthesia and respiratory care business line. This is expected
to result in a well-regarded, highly diversified business segment
with annual sales of $530 million or higher. The acquisitions
will also extend the company supply chain. Teleflex intends to
achieve this through improved relationships with group purchasing
Limerick, Pennsylvania-based Teleflex' focus on profitable and
consistent growth is expected to yield results, helped by
demographic trends and barriers to entry in the industry. The
recent divestiture of its OEM Orthopedic division is expected to
aid the company's strategy of new product introduction, and
investment in innovative technologies. This will accelerate the
Teleflex top-line in the years ahead.
) which operate in similar business segments present a tough
competitive landscape for Teleflex. Additionally, the company
operates in a seasoned regulatory environment. The demand for its
products is susceptible to healthcare reimbursement systems in
the domestic as well as the international markets.
Teleflex currently carries a Zacks #2 Rank, which translates into
a short-term Buy rating.